Tanzawa, Aika
Saito, Kengo
Ota, Masayuki
Takahashi, Koji
Ohno, Izumi
Hanazawa, Toyoyuki
Uzawa, Katsuhiro
Takiguchi, Yuichi http://orcid.org/0000-0001-6059-7476
Funding for this research was provided by:
the Ministry of Education, Culture, Sports, Science and Technology in Japan (Kiban-C #20K08561, the Kanto Academic Alliance for Fostering Cancer Professionals)
Article History
Received: 29 November 2023
Accepted: 6 March 2024
First Online: 16 March 2024
Declarations
:
: In relation to conflict of interests pertaining to the present study, Izumi Ohno has received lecture fees from AstraZeneca, Daiichi-Sankyo, Novartis, Chugai pharmaceutical co., Ono pharmaceutical co., Bristol Meyers Squib, and Merck Sharp and Dohme. Toyoyuki Hanazawa has received lecture fees from Ono pharmaceutical co., and Merck Sharp and Dohme. Yuichi Takiguchi has received lecture fees from AstraZeneca, Daiichi-Sankyo, Novartis, Chugai pharmaceutical co., Bristol Meyers Squib, Pfizer, and Merck Sharp and Dohme, and research funds from AstraZeneca, Chugai pharmaceutical co., Ono pharmaceutical co., Pfizer, and Merck Sharp and Dohme. The other authors have no conflict of interests to declare.
: The study protocol was reviewed and approved by the institutional review board of Graduate School of Medicine, Chiba University (approval number M10019). The need to obtain patient written informed consent for participation in this study was waived and an opt-out method for obtaining consent was applied based on indication from the IRB, because of the retrospective nature of the study and absence of any intervention.